血液病患者SARS-CoV-2感染早期治疗结局
该回顾性研究纳入2021年3月至2022年7月间328例接受早期抗病毒或抗刺突单克隆抗体治疗的轻/中度COVID-19血液肿瘤患者,主要复合终点为治疗失败。治疗失败独立预测因素为高龄、疫苗剂数少和单克隆抗体治疗,Omicron期失败率低于前Omicron期(7.8% vs 36.8%,p<0.001)。
要点
- 血液肿瘤患者早期治疗失败率9.5%,Omicron期为7.8%,前Omicron期为36.8%。
- 治疗失败独立预测因素为高龄、疫苗剂数少和接受单克隆抗体治疗。
- Omicron期发生重症COVID-19者死亡率为26%,COVID-19相关总死亡率为3.4%。
核心结论
- 血液肿瘤患者早期治疗失败风险显著,即使Omicron期亦如此,且死亡率高。
研究设计与样本
- 回顾性研究,纳入2021年3月至2022年7月期间接受轻/中度COVID-19治疗的血液肿瘤患者328例。
- 患者接受单克隆抗体(n=120,37%;其中sotrovimab n=73)或抗病毒药物(n=208,63%;其中nirmatrelvir/ritonavir n=116),症状出现后中位2天给药。
- 111例(33.8%)为非霍奇金淋巴瘤,89例(27%)为移植/CAR-T受者。
- 大多数感染(n=309,94%)发生在Omicron期。
主要发现
- 31例(9.5%)发生治疗失败(重症COVID-19或COVID-19相关死亡)。
- 治疗失败的独立预测因素为高龄、疫苗剂数少和接受单克隆抗体治疗。
- Omicron期失败率低于前Omicron期(7.8% vs 36.8%,p<0.001)。
- Omicron期治疗失败的预测因素为年龄、疫苗剂数少和急性髓系白血病/骨髓增生异常综合征诊断。
- 病毒排出时间延长的独立预测因素为年龄、合并症、诊断时住院、非霍奇金淋巴瘤/慢性淋巴细胞白血病、接受单克隆抗体治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcome of early treatment of COVID-19 with antivirals or anti-spike monoclonal antibodies (MABs) in patients with haematological malignancies (HM) is unknown. A retrospective study of HM patients treated for mild/moderate COVID-19 between March 2021 and July 2022 was performed. The main composite end-point was treatment failure (severe COVID-19 or COVID-19-related death). We included 328 consecutive patients who received MABs (n = 120, 37%; sotrovimab, n = 73) or antivirals (n = 208, 63%; nirmatrelvir/ritonavir, n = 116) over a median of two days after symptoms started; 111 (33.8%) had non-Hodgkin lymphoma (NHL); 89 (27%) were transplant/CAR-T (chimaeric antigen receptor T-cell therapy) recipients. Most infections (n = 309, 94%) occurred during the Omicron period. Failure developed in 31 patients (9.5%). Its independent predictors were older age, fewer vaccine doses, and treatment with MABs. Rate of failure was lower in the Omicron versus the pre-Omicron period (7.8% versus 36.8%, p < 0.001). During the Omicron period, predictors of failure were age, fewer vaccine doses and diagnosis of acute myeloid leukaemia/myelodysplastic syndrome (AML/MDS). Independent predictors of longer viral shedding were age, comorbidities, hospital admission at diagnosis, NHL/CLL, treatment with MABs. COVID-19-associated mortality was 3.4% (n = 11). The mortality in those who developed severe COVID-19 after early treatment was 26% in the Omicron period. Patients with HM had a significant risk of failure of early treatment, even during the Omicron period, with high mortality rate.
引用
- Mikulska M, Testi D, Russo C, et al. Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders. Br J Haematol. 2023. PMID: 36806152. doi:10.1111/bjh.18690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。